This approach could potentially trigger synthetic lethal cell death specifically in cell lines that overexpress SLC7A11 and are thus sensitized to glucose deprivation, offering a promising avenue for targeted cancer therapies (43) (Figure 4). The gene discussed is SLC7A11; the disease is cancer.